Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 3;10(5):e02046-22. doi: 10.1128/spectrum.02046-22

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Debes et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

PMC Copyright notice

FIG 1 — Spike IgG serum antibodies and live-virus neutralizing antibody titers (NT) against the vaccine strain (WA-1). Data are shown for three time points: within 14 to 44 days after dose 2 (time point 1), at least 8 months after dose 2 (time point 2), and within 14 to 44 post-boost (time point 3). Across the three time points, respectively: 396 (78%), 739 (84%), and 215 (79%) were women; 484 (95%), 845 (96%), and 263 (96%) were non-Hispanic/Latino; 395 (78%), 723 (82%), and 238 (87%) were white; 383 (76%), 657 (75%), 225 (82%) received Pfizer for their primary series; and the median age (interquartile range) was 39.9 (32.4, 51.9), 43.0 (35.1, 53.5), and 44.9 (34.3, 55.6).